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during 30 years, in order to realize a cost-effectiveness analysis.
The probabilities to be entered in the model were deﬁned after
an important review of literature. Efﬁcacy was assessed by 
incidence of CRC and life expectancy in the model. The dis-
counted costs considered were related to cancer (diagnostic,
treatment), chemoprevention (treatment, side effects) and screen-
ing (colonoscopy with or without polypectomy, complications),
under a society-based perspective restricted to the health sector.
RESULTS: When a 80% reduction in CRC through screening
and a 30% reduction of adenomas through chemoprevention
were assumed, the most effective strategies were also the cheap-
est. While 5090 CRC for 100,000 persons are expected in a pop-
ulation without intervention, 1380 CRC could be avoided with
a chemoprevention, 3230 with a colonoscopic program of sur-
veillance and 3800 when associating colonoscopy and aspirin.
The life expectancy in the model is 16.22 years with a cost-
effectiveness ratio (CER) of 696€ for strategy (1), and 16.63
years with a CER of 371€ for strategy (4). With a percentage of
amelioration through screening reduced to 50%, the results
remains in favour of the strategies (2) and (4), while strategy (3)
is no longer cost-effective. CONCLUSION: Results emphasize
the importance of a regular surveillance. The cost of cancer is
high enough to condemn the absence of prevention.
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OBJECTIVES: To evaluate the cost-effectiveness of cisplatin-
etoposide (PE), cisplatin—winorelbine (PN) and cisplatin-
gemcytabine (PG) combinations recommended in NSCLC 
treatment in Poland. METHODS: Medical care utilization data
and survival data were collected retrospectively in medical
centers in Poland (Warsaw, Poznan, Cracow and Wroclaw);
among patients with advanced non-small cell lung cancer (stage
IIIb and IV), who were treated with one of the analyzed regi-
mens and had not had surgical intervention. The payers’ per-
spective, which in Poland was The Regional Insurance Agenda,
were chosen for the calculation of cost. Only direct medical care
cost were assessed. All medical care consumption (including cost
of diagnostic tests, hospitalization, ambulatory care and med-
ications) were estimated from the patients’ chart and the infor-
mation of costs were derived from the Financial Departament in
each hospital. All cost were in polish zloty (in 2001: 1$ = 4.14
zloty. RESULTS: The highest average cost of one patients
chemotherapy was for the PG regimen (26,016 polish zloty),
almost two times higher that for PN—11,642zl and PE—10,350
zl. The cost-effectiveness ratio was 30,850zl, 37,792zl, and
56,983zl per life year gained for PN, PE, and PG, respectively.
Sensitivity analysis conﬁrmed that the factors that affect the cost
of treatment had not had an inﬂuence for the ﬁnal results.
Whereas the value of cost-effectiveness ratios were sensitive to
the factors that affect the effectiveness of chemotherapy. CON-
CLUSIONS: Our analysis showed that the combination of cis-
platin and winorelbine is more cost-effective in the treatment of
advanced NSCLC compared to cisplatin—etoposide and cis-
platin—gemcytabine regimens.
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OBJECTIVES: ALCEA (Advanced Lung Cancer Economic
Assessment)—an observational cost-of-illness study—was aimed
to investigate the economic proﬁle of the advanced Non-Small
Cell Lung Cancer (NSCLC) in Italy. METHODS: Information
on health care resource utilization was collected on 189 patients
affected by advanced NSCLC and treated with ﬁrst line
chemotherapy (1stL), second line chemotherapy (2ndL) or Sup-
portive Therapy (ST), for a 6-month period or until death.
Resources were costed according to current Italian tariffs.
Average management cost per patient and monthly average per
patients costs (MAPC) were calculated. RESULTS: Overall 
125pts received 1stL, 62 2ndL and 53 ST. Average cost per
patient was 8.265€, 5.148€ and 3.389€ in 1stL, 2ndL and ST,
respectively. Hospitalization was the main constituent of cost in
all lines accounting for 62% in 1st L, 68% in 2nd line and 77%
in ST. Costs of drugs prescribed at home ranked second in all
lines (12%, 11% and 10%, respectively). Cost of radiotherapy
was negligible in 2ndL while ranked third in 1stL and S (10%
and 9% of mean cost, respectively). Monthly cost of chemother-
apy was higher in 2ndL than in 1stL as more expensive agents
are frequently used. Due to their general conditions, patients in
2ndL generate higher adverse event costs (MAPC 269€ vs. 218€
in 1stL) and ST patients determined higher hospitalisation costs
(MAPC 2.298€ vs. 1870€ in 2ndL and 1.156€ in 1stL). CON-
CLUSIONS: NSCLC management imposes a remarkable burden
on the Health Care system in the advanced disease stages.
Although costs reduce from 1stL to 2ndL and to SC, even the
latter has a signiﬁcant economic impact. Strategies that can
reduce hospitalization (including oral drugs or home assistance
burden) could help lowering the cost of advanced NSCLC.
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OBJECTIVES: Gemcitabine (Gemzar) belongs to new third-
generation chemotherapeutic agents that are now commonly
used in combination with cisplatin or carboplatin in advanced
non-small cell lung cancer (NSCLC). We compared the direct
health care costs of a gemcitabine/cisplatin regimen (Gem/Cis)
with paclitaxel/carboplatin (Pac/Car) and vinorelbine/cisplatin
(Vin/Cis) regimens in the treatment of NSCLC in France.
METHODS: The economic analysis was performed based on
chemotherapy and medical resource utilisation by 612 patients
in the randomised, controlled trial published by Scagliotti et al.
(2002), which found no difference in efﬁcacy between the three
regimens. Trial data were combined with unit cost data from
French ofﬁcial DRG charges for chemotherapy medication (reim-
bursed over the DRGs), chemotherapy administration, hospital-
